Kopp Family Office Reduces Stake in Viridian Therapeutics by $3.5 Million
Kopp Family Office, LLC, reduced its stake in Viridian Therapeutics (NASDAQ:VRDN) by 117,878 shares, valued at approximately $3.5 million, during the first quarter of 2026. The fund now holds 55,295 shares, representing 0.7% of its AUM. The stock has underperformed the S&P 500 by about 28 percentage points over the past year.
Tickers: $VRDN
Topics: Kopp Family Office SEC Filing Stock Position Reduction Viridian Therapeutics